Homoki J, Garbrecht D, Loos U, Teller W M
Monatsschr Kinderheilkd. 1985 Aug;133(8):532-6.
91 children (70 girls and 21 boys) aged between 5 and 16 years were treated orally with thyroid hormones for euthyroid juvenile goiter. Maximally for 54 months. 16.5% of the children had a goiter size I, 69.2% size II, and 14.3% size III. 59 patients were treated for an average of 15.3 months with a mean daily dose of 90.9 micrograms thyroxine (T4) plus 18.2 micrograms triiodothyronine (T3) per m2 body surface. 32 patients received T4 in a mean daily dose of 88 micrograms/m2 body surface for an average of 7.5 months. The patients were examined 3-monthly in the outpatient department. The correlations between doses of thyroid hormones and serum concentrations of PBI or T4 were evaluated retrospectively using treatment records. The correlations were significant with r = 0.310 (T4 + T3) and r = 0.138 (T4). The large spread of PBI or T4 concentrations proved that compliance and enteral resorption influence the efficacy of treatment with thyroid hormones. Despite the different length of therapy 73% of patients on combined therapy and 72% of patients on thyroxine alone achieved a reduction of the size of their goiter. In both treatment groups the results of therapy were best (70% improvement) when the T4-concentrations ranged between 9.4 and 10.7 micrograms/dl. The number of complaints per patients during therapy was independent of the hormone dosages. During the first seven follow-up examinations patients on the combined hormone schedule uttered an average of 2.5 complaints, while the patients on thyroxine alone had an average of 1.1 complaints.
91名年龄在5至16岁之间的儿童（70名女孩和21名男孩）因甲状腺功能正常的青少年甲状腺肿接受了甲状腺激素口服治疗，最长治疗54个月。16.5%的儿童甲状腺肿为I度，69.2%为II度，14.3%为III度。59名患者平均接受了15.3个月的治疗，每平方米体表面积的平均每日剂量为90.9微克甲状腺素（T4）加18.2微克三碘甲状腺原氨酸（T3）。32名患者每平方米体表面积平均每日接受88微克T4治疗，平均治疗7.5个月。患者每3个月在门诊部接受检查。利用治疗记录回顾性评估甲状腺激素剂量与血清PBI或T4浓度之间的相关性。相关性显著，T4加T3治疗时r = 0.310，T4治疗时r = 0.138。PBI或T4浓度的广泛分布证明依从性和肠道吸收会影响甲状腺激素治疗的疗效。尽管治疗时间不同，但联合治疗组73%的患者和仅接受甲状腺素治疗组72%的患者甲状腺肿大小有所减小。在两个治疗组中，当T4浓度在9.4至10.7微克/分升之间时，治疗效果最佳（改善率70%）。治疗期间每位患者的不适主诉数量与激素剂量无关。在前七次随访检查中，联合激素治疗方案的患者平均有2.5次不适主诉，而仅接受甲状腺素治疗的患者平均有1.1次不适主诉。
